



Announcement Summary

Entity name

PARADIGM BIOPHARMACEUTICALS LIMITED..

Date of this announcement

Friday December 20, 2024

The +securities the subject of this notification are:

Other

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
New class - code to be confirmed	Unlisted performance rights with 3 year expiry	6,558,600	20/12/2024

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

PARADIGM BIOPHARMACEUTICALS LIMITED..

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

169346963

1.3 ASX issuer code

PAR

1.4 The announcement is

New announcement

1.5 Date of this announcement

20/12/2024



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

Other

Please specify

Issue of performance rights to Directors and employees as approved at Nov 2024 AGM.

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class)

New +securities

ASX +security code

New class - code to be confirmed

+Security description

Unlisted performance rights with 3 year expiry

+Security type

Other

ISIN code

Date the +securities the subject of this notification were issued

20/12/2024

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

The material terms of the performance rights were set out in the Notice of Annual General Meeting announcement lodged with the ASX on 25 October 2023

Any other information the entity wishes to provide about the +securities the subject of this notification

Each Performance Right converts to one Share when meeting the primary goal at the end of a vesting period.

Please provide any further information needed to understand the circumstances in which you are notifying the issue of these +securities to ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

N/A

Issue details

Number of +securities

6,558,600

Were the +securities issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Offered as long-term incentive.

Purpose of the issue

Other

Additional Details

A long-term incentive to employees

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
PAR : ORDINARY FULLY PAID	389,303,603

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
PARAAB : OPTION EXPIRING 09-FEB-2026 EX \$0.65	2,500,000
PARAT : ORDINARY FULLY PAID RESTRICTED	125,000
New class - code to be confirmed : Unlisted performance rights with 3 year expiry	6,558,600



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

Yes

5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

19/11/2024